Alps Advisors Inc. Has $25.49 Million Stock Position in Abbott Laboratories $ABT

Alps Advisors Inc. boosted its position in Abbott Laboratories (NYSE:ABT) by 76.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 190,327 shares of the healthcare product maker’s stock after acquiring an additional 82,455 shares during the period. Alps Advisors Inc.’s holdings in Abbott Laboratories were worth $25,492,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. a16z Perennial Management L.P. bought a new position in shares of Abbott Laboratories in the 3rd quarter worth $312,000. Canada Post Corp Registered Pension Plan raised its holdings in Abbott Laboratories by 192.0% during the third quarter. Canada Post Corp Registered Pension Plan now owns 144,066 shares of the healthcare product maker’s stock worth $19,177,000 after buying an additional 94,730 shares during the last quarter. Greater Midwest Financial Group LLC lifted its stake in shares of Abbott Laboratories by 15.8% in the third quarter. Greater Midwest Financial Group LLC now owns 28,958 shares of the healthcare product maker’s stock valued at $3,879,000 after buying an additional 3,948 shares in the last quarter. Concord Wealth Partners grew its holdings in shares of Abbott Laboratories by 3.0% during the third quarter. Concord Wealth Partners now owns 13,452 shares of the healthcare product maker’s stock valued at $1,802,000 after buying an additional 387 shares during the last quarter. Finally, Financial & Tax Architects LLC increased its position in shares of Abbott Laboratories by 5.8% during the third quarter. Financial & Tax Architects LLC now owns 60,069 shares of the healthcare product maker’s stock worth $8,046,000 after acquiring an additional 3,291 shares in the last quarter. 75.18% of the stock is owned by institutional investors and hedge funds.

Abbott Laboratories Stock Up 1.6%

Abbott Laboratories stock opened at $110.86 on Friday. The firm has a 50 day simple moving average of $120.86 and a 200 day simple moving average of $126.90. The company has a current ratio of 1.70, a quick ratio of 1.24 and a debt-to-equity ratio of 0.23. Abbott Laboratories has a 1-year low of $105.27 and a 1-year high of $141.23. The firm has a market capitalization of $192.77 billion, a price-to-earnings ratio of 29.80, a P/E/G ratio of 1.76 and a beta of 0.75.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting the consensus estimate of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.94%. The company had revenue of $11.46 billion during the quarter, compared to analysts’ expectations of $11.80 billion. During the same quarter in the previous year, the company earned $1.34 earnings per share. Abbott Laboratories’s revenue for the quarter was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, February 13th. Investors of record on Thursday, January 15th will be given a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.3%. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.59. The ex-dividend date is Thursday, January 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 67.74%.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Barclays dropped their price target on shares of Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating on the stock in a research report on Monday, February 2nd. Oppenheimer dropped their target price on Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Mizuho upped their price target on Abbott Laboratories from $135.00 to $140.00 and gave the stock a “neutral” rating in a report on Tuesday, October 14th. Royal Bank Of Canada dropped their price objective on Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. Finally, William Blair upgraded shares of Abbott Laboratories to a “strong-buy” rating in a research note on Thursday, November 20th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $137.05.

Insider Buying and Selling

In other news, Director Daniel J. Starks acquired 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 4th. The shares were bought at an average cost of $108.73 per share, with a total value of $1,087,300.00. Following the acquisition, the director owned 6,738,817 shares in the company, valued at approximately $732,711,572.41. This represents a 0.15% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.46% of the stock is currently owned by corporate insiders.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.